Ekstrom-Smedby K. Epidemiology and etiology of non-Hodgkins lymphoma – a review. Acta Oncol 2006 45: 258-271
Cancer in Norway 2018, Cancer Registry of Norway, Institute of Population-based Research. Oslo, Norway
Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non- Hodgkinss lymphoma. J Clin Oncol 1999; 19: 1244?53.
Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkinss disease: Cotswolds meeting. J Clin Oncol 1989; 7: 1630-6.
Overlevelse og prognostiske faktorer
Foss Abrahamsen A, Hannisdal E, Nome O et al. Clinical stage I and II Hodgkinss disease: Long-term results of therapy without laparatomy. Experience at one institution. Ann Oncol 1996; 7: 145-150.
Hasenclever D, Diehl V. A prognostic score for advanced Hodgkinss disease. International Prognostic Factors Project on Advanced Hodgkins?s Disease. N Engl J Med. 1998; 339: 1506-14.
Cancer in Norway 2013, Cancer Registry of Norway, Institute of Population-based Research. Oslo, Norway
The International non-Hodgkinss lymphoma prognostic factor project. A predictive model for aggressive non- Hodgkinss lymphoma N Engl J Med 1993; 329: 987-94.
Solal Séligny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258-65.
Histologi, immunhistojemi og genetiske undersøkelser
Den norske patologforenings lymfomkode-utvalg: Forslag til Norsk SNOMED for lymfomer, oktober 2001.
Swerdlow SH, Campo E, Harris NL, Jaffe E, Pileri A, Stein H, et al. WHO Classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARCH Press. 2008(4th Edition).
Behandling av non-Hodgkins lymfom
Evensen SA, Brinch L, Tjonnfjord G et al. Estimated 8- year survival of more than 40 % in a population-based study of 79 adult patients with acute lymphoblastic leukaemia. Br J Haematol. 1994 Sep; 88(1): 88-93.
Småcellet lymfocytært lymfom/kronisk lymfatisk leukemi
del Giglio A, Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995; 85: 307-18
Eichhorst BF, Bursch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:885-891.
Wierda W, OBrian S, Wen S et al. Chemoimmunotherapy with Fludarabine,Cyclophosphamide, and Rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005. 23:4070-4078.
Rai KR. Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia. Semin Oncol. 2006 Apr;33(2 Suppl 5):S15-22.
Keating MJ, OBrian S, Albitar M et al. Early results of chemoimmunotherapy regimen of fludarabin, cyclophosphamide and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005 23:4079-88
Binet JL, Caligaris-Cappis F, Catovsky D et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood. 2006 Feb 1;107(3):859-61. Epub 2005 Oct 13. Review.
Marginalsone B-celle lymfomer
Isaacson PG. Extranodal marginal zone B-cell lymphoma of mucosa-associated lympoid tissue type. ASCO educational 2001. Perry MC (editor).
Bertoni F, Zucca E. State-of-the-art therapies: Marginal-zone lymphoma. J Clin Oncol 2005 23:6415-20
Wotherspoon AC, Doglioni C, Diss TC et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa associated lymphoid tissue after eradication of Helicobacter pylori. Lancet 1993; 342: 575-7.
Wundisch T, Thiede C, Morgner A, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter Pylori eradication. J Clin Oncol 2005, 23 (31), 8018-24
Waldenstroms macroglobulinemi – lymphoplasmacytisk lymfom
Treon SP, Gertz MA, Dimopoulos M et al. Update on treatment recommodations from the Third International Workshop on Waldenstroms macroglobulinemia. Blood 2006 107(9), 3442-46.
Ozsahin M, Tsang RW, Poortmans P et al. Outcomes and patterns of failure in solitary plasmacytoma: a multicenter rare cancer network study of 258 patients. Int J Radiation Oncology Biol Phys 2006 1: 210-17
Czuczman MS, Grillo-Lopez AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-76.
Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 2005 106(12):3725-32.
van Oers MH, Klasa R, Marcus RE et al., Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkins's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. EORTC Lymphoma Group and HOVON. Blood, July 2006
van Oers MHJ, Van Glabbeke M, Giurgea L, Klasa R 4, Marcus RE, Wolf M, Kimby E, van t Veer M, Vranovsky A, Holte H, Anton Hagenbeek A. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkins’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized Intergroup study. J Clin Oncol 2010; 28: 2853-8.
Forstpointner R, Dreyling M, Repp R, et al. (German Low-Grade Lymphoma Study Group) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 2004 104(10):3064-71.
Hagenbeek A, Eghbali H, Monfardini S, et al Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkins's lymphoma. J Clin Oncol. 2006 Apr 1;24(10):1590-6.
Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkins's lymphoma: results from the randomized European CUP trial. J Clin Oncol. 2003, 21(21):3894-6.
Hinault-Berger M, Ifrah N and Solal-Celigny P. Intensive therapies in follicular non-Hodgkins lymphomas. Blood. 2002; 100: 1141-52. Review.
Kimby E, Bjørkhom M, Gahrton G, Glimelius B, Hagberg H, Johansson B et al. Klorambucile/prednisone vs. CHOP in symptomatic low-grade non- Hodgkinss lymphoms: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 1994; Suppl 2: 67-71.
Mauch P. Follicular non-Hodgkinss lymphoma: the role of radiation therapy. Ann Hematol. 2001;80 Suppl 3: B63-5. Review.
Mc Laughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti- CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33.
Nickenig C, Dreyling M, Hoster E, et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.Cancer 2006 107(5):1014-22.
Reiser M, Diehl V. Current treatment of follicular non-Hodgkinss lymphoma. Eur J Cancer. 2002 Jun; 38(9): 1167-72. Review.
Solal Celigny P, Lepage E, Brousse N et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med 1993; 329: 1608-14.
Ghielmini M et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103: 4416-23.
Witzig TE et al. Randomized controlled trial of Yttrium-90-labeled Ibritumomab Tiutexan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade follicular or transformed B-cell non-Hodgkins’s lymphoma. J Clin Oncol 2002; 20: 2453-63.
Marcus Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-23.
Weisenburger DD, Armitage JO. Mantle cell lymphoma – an entity comes of age. Blood 1996; 87: 4483– 4494.
Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995; 85: 1075– 1082.
Hiddemann W, Unterhalt M, Herrmann R, et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 1998; 16: 1922–1930.
Freedman AS, Neuberg D, Gribben JG, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998;
Geisler CH, Kolstad A, Laurell A et al.,The Mantle Cell Lymphoma Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive 1st-line immunochemotherapy and autologous stem-cell transplantation (ASCT). Blood. 2009 Dec 23. [Epub ahead of print]
Dreyling M, Lenz G, Hoster E. et al.Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005 Apr 1;105(7):2677-84.
Diffuse storcellete B-celle lymfomer
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, MorelP, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma.N Engl J Med. 2002; 346: 235–42.
Cooper IA, Wolf MM, Robertson TI, Fox RM, Matthews JP, Stone JM et al. Randomised comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkins’s lymphomas. J Clin Oncol 1994; 12: 769–78.
Fisher RI, Gaynor E, Dahlberg H, Oken MM, Grogan TM, Mize EM et al. A phase III comparison of CHOP versus m-BACOD versus ProMACE- CytaBOM versus MACOP-B in patients with intermediate or high gar non- Hodgkins’s lymphoma. N Engl J Med 1993; 328: 1002–6.
Jerkemann M, Cavallin-Ståhl E, Hagberg H and Kvaløy S. CHOP versus MACOP-B in high grade malignant non-Hodgkins’s lymphoma – a prospective randomised study by the Nordic lymphoma study group. Ann Oncol 1996; 7: 78a. Mirza MR and Brincker H. MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. Acta Oncol 1991; 30: 17–21.
Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady- Lyons N,Agus DB, Goy A, Jurcic J, Noy A, O'Brien J, Portlock CS, Straus DS, Childs B,Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkins’s lymphoma. J Clin Oncol. 1999; 17: 3776–85.
Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in
British Columbia. J Clin Oncol 2005; 23: 1-7.
Pfreundschuh M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of DSHNHL. Blood 2004; 104: 626-41
Pfreundschuh M et al. Two-weekly or 3-weekly CHOP chemotherapy with or witot etoposide for the treatment of elderly patients with aggressive lymphomas: Results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-41.
Pfreundschuh M, Trumper L, Osterborg A: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 7(5):379-91.
Daimond C, Taylor TH, Im T et al. Improved survival and chemotherapy response among patients with AIDS-related non-Hodgkins's lymphoma receiving highly active antiretroviral therapy. Hematol Oncol. 2006 Apr 10;
Weiss R, Mitrou P, Arasteh K et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial. Cancer. 2006 Apr 1;106(7):1560-8.
Mounier N, Spina M, Gabarre J et al. AIDS-related non-Hodgkins lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood. 2006 May 15;107(10):3832-40.
Holte H, Smeland S, Blystad A-K, Kvaloy S Hammerstrom J og Tjonnfjord G. Intensiv kjemoterapi ved Burkitts lymfom og aggressivt non-Hodgkins’s lymfom. Tidsskr-Nor Lægeforen. 2002; 122: 364–9.
Smeland S, Blystad A K, Kvaløy S et al. Treatment of Burkitt’s / Burkitt-like lymphoma in adolescents and adults. A twenty year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann. Oncol. 2004; 15: 1072-8.
Modne T-celle og NK cellelymfomer
Siegel RS, Pandolfino T, Guitart J, et al. Default Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 2000; 18: 2908–25.
Stein H, Foss HD, Durkop H, Marafioli T, Delsol G, Pulford K et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000; 96: 3681–95. Review.
Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26: 4124-30.
CNS profylakse og behandling
Hollender A, Kvaløy S, Skovlund E, Lote K and Holte H. Central nervous system involvement following diagnosis of non-Hodgkins’s lymphoma: a risk model. Ann Oncol. 2002 Jul; 13(7): 1099–107.
Hollender A, Kvaløy S, Lote K, Nome O and Holte H. Prognostic factors in 140 adult patients with non- Hodgkins’s lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer. 2000 Sep; 36(14): 1762–8.
Primære CNS lymfomer
Abrey LE, Yahalou J and DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000; 18: 3144–50.
Goldkuhl C, Ekman T, Wiklund T and Telhaug R. Age-adjusted chemotherapy for primary central-nervous system lymphoma – a pilot study. Acta Oncol. 2002; 41: 29–35.
Lymfomer i gastrointestinaltraktus
Koch P, Grothaus-Pinke B, Hiddemann W Wiilich N, Reers B, del Valle F et al. Primary lymphoma of the stomach: Three-year results of a prospective multicenter study. Ann Oncol 1997; 8 (Suppl 1): 85–8. Wotherspoon AC, Doglioni C, Diss T C, Pan L, Moschini A, de Boni M et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa associated lymphoid tissue after eradication of Helicobacter pylori. Lancet 1993; 342: 575–7.
Zucca E, Roggero E, Bertoni F, et al. Primary extranodal non-Hodgkins’s lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Ann Oncol 1999; 10: 1023–33.
Lote K, Holte H, Nome O, Langholm R and Kvaløy S. Stage I high-grade non-Hodgkins’s lymphoma. Acta Oncol. 2000; 39(7): 865–72.